<DOC>
	<DOCNO>NCT01700413</DOCNO>
	<brief_summary>While several study report increase dos daunorubicin first line treatment Acute Myeloid Leukemia ( AML ) , similar experience idarubicin initial treatment AML . As idarubicin common treatment use AML , need find optimal dose combination idarubicin , cytarabine G_CSF , explore combination improve outcomes current treatment AML . The aim dose-finding study find optimal dose combination idarubicin , cytarabine G-CSF could improve response rate , reduce relapse improve survival patient primary acute myeloid leukemia . This could significant advance field treatment outcomes stabilize last 15 year . This study basis prospective , randomize , multicenter trial compare idarubicin maximum tolerate dose , compare standard treatment idarubicin cytarabine , include raise arm G-CSF . The dose 12 mg/m2 administer control arm future randomize study , investigate benefit enhance dose identify optimal phase II pilot study .</brief_summary>
	<brief_title>Efficacy Toxicity Increasing Doses Idarubicin , Cytarabine G-CSF Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Informed consent signature Patients newly diagnose AML , classify accord WHO criterion . Age equal 18 less equal 70 year . Patients previously treat chemotherapy AML hydroxyurea . Acute promyelocytic leukemia ( 15 ; 17 ) . Blast crisis chronic myeloid leukemia . Leukemias appear myeloproliferative neoplasm . Leukemias ensue myelodysplastic syndrome 6 month . Presence malignancies activity . AML secondary chemoradiotherapy treatment malignancy . Abnormal renal hepatic function , creatinine value / bilirubin 2 time normal limit value , except alteration attributable leukemia . Patients markedly reduce ejection fraction ( le 45 % ) , symptomatic heart failure , normal value center . Patients serious concomitant psychiatric neurological disease . HIVpositive . Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>acute</keyword>
	<keyword>myeloid</keyword>
	<keyword>leukemia</keyword>
	<keyword>CETLAM</keyword>
	<keyword>Idarubicin</keyword>
</DOC>